Data edition of
Residue An evidence-graded reference for peptide science

The editorial team

Residue is written and reviewed by the Residue Editorial Team. We do not ask you to trust a name: every factual statement links to the public record it came from, so any reader can repeat our check.

An open notebook with blank ruled pages, a fountain pen and a squared stack of blank index cards

Written by

Residue Editorial Team

Researches, drafts and maintains every monograph and comparison, and runs the data pipeline that refreshes registry and label records.

Reviewed by

Residue Editorial Team

Every page passes the five-stage review below before it is published and again whenever its grade or a cited fact changes. The byline on each page shows the date of its latest review.

Current data snapshot

October 19, 2026

The retrieval date of the PubMed, ClinicalTrials.gov, PubChem and FDA records every page is built from.

How a page is reviewed

  1. 1

    Snapshot

    A build script pulls PubMed, ClinicalTrials.gov, PubChem and openFDA records and stores them with a retrieval date. Prose may only cite records in that snapshot.

  2. 2

    Resolution

    Every citation marker must resolve to a stored PMID, NCT number, CID or FDA application. One unresolved marker fails the whole build, so nothing ships with a dangling reference.

  3. 3

    Source check

    A reviewing editor reads each sentence against the abstract, label or registry record it cites. If the source does not say it, the sentence is cut or rewritten. This is a different pass from drafting.

  4. 4

    Grade check

    The headline grade and every per-effect grade are re-derived from the rules on the methodology page. Fragments do not inherit a parent drug’s trials; registrations do not count as results.

  5. 5

    Compliance check

    Pages are checked for anything that reads as dosing advice, treatment advice, a product recommendation, a price or a vendor. Dose tables reproduce what trials registered, with no instructions.

What “reviewed” means here — and what it does not

Review on Residue is an editorial check of accuracy against sources and of compliance with our rules. It is not a clinical or medical review, and the team does not claim individual medical, pharmacy or academic credentials on this site. Nothing here is medical advice; the compounds discussed are, unless an FDA label says otherwise, research substances.

That is a deliberate choice. A reference that cites everything can be checked by anyone; a credential on a byline cannot substitute for that. If a qualified individual reviewer joins, they will be named here with verifiable credentials and their conflicts of interest.

Publication standards

  • Every claim cites PubMed, ClinicalTrials.gov, PubChem, openFDA/DailyMed or an FDA web page.
  • Grades follow the published methodology, and every page links to it.
  • No dosing instructions, product recommendations, prices or vendors.
  • Each page shows when it was first published, last updated and last reviewed, and the date of the registry snapshot.

Conflicts of interest

Residue has no commercial relationships with peptide manufacturers, compounding pharmacies, clinics or vendors, and carries no advertising or affiliate links. See disclosures and the editorial policy, which includes the corrections log.